Eric Venker Roivant Sciences Ltd. (ROIV) insider trading activity

Eric Venker is President & Immunovant CEO of Roivant Sciences Ltd.. Currently has a direct ownership of 1.65 Million shares of ROIV, which is worth approximately $33.6 Million. The most recent transaction as insider was on May 01, 2023, when has been sold 61,155 shares (Common Shares) at a price of $8.59 per share, resulting in proceeds of $525,321. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.65M

9.94% 3M change

123.3% 12M change

Total Value Held $33.6 Million

Eric Venker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 01 2023	SELL Open market or private sale	$525,321 $8.59 p/Share	61,155 Reduced 8.3%	675,768 Common Shares
May 01 2023	BUY Exercise of conversion of derivative security	$235,446 $3.85 p/Share	61,155 Added 7.66%	736,923 Common Shares
Apr 28 2023	SELL Open market or private sale	$642,220 $8.47 p/Share	75,823 Reduced 10.09%	675,768 Common Shares
Apr 28 2023	BUY Exercise of conversion of derivative security	$291,918 $3.85 p/Share	75,823 Added 9.16%	751,591 Common Shares
Apr 27 2023	SELL Open market or private sale	$625,604 $8.51 p/Share	73,514 Reduced 9.81%	675,768 Common Shares
Apr 27 2023	BUY Exercise of conversion of derivative security	$283,028 $3.85 p/Share	73,514 Added 8.93%	749,282 Common Shares
Apr 26 2023	SELL Open market or private sale	$631,365 $8.66 p/Share	72,906 Reduced 9.74%	675,768 Common Shares

Apr 26 2023	BUY Exercise of conversion of derivative security	$280,688 $3.85 p/Share	72,906 Added 8.87%	748,674 Common Shares
Apr 20 2023	SELL Payment of exercise price or tax liability	$127,221 $8.8 p/Share	14,457 Reduced 2.09%	675,768 Common Shares
Mar 23 2023	SELL Other acquisition or disposition	$103,616 $7.3 p/Share	14,194 Reduced 2.01%	690,225 Common Shares
Feb 22 2023	SELL Other acquisition or disposition	$100,763 $8.43 p/Share	11,953 Reduced 1.67%	704,419 Common Shares
Jan 24 2023	SELL Other acquisition or disposition	$111,767 $8.56 p/Share	13,057 Reduced 1.79%	716,372 Common Shares
Jan 05 2023	SELL Open market or private sale	$192,776 $8.02 p/Share	24,037 Reduced 3.19%	729,429 Common Shares
Jan 03 2023	SELL Open market or private sale	$698,942 $7.32 p/Share	95,484 Reduced 11.25%	753,466 Common Shares
Dec 30 2022	SELL Open market or private sale	$190,088 $8.0 p/Share	23,761 Reduced 2.72%	848,950 Common Shares
Dec 23 2022	SELL Other acquisition or disposition	$113,820 $7.1 p/Share	16,031 Reduced 1.75%	901,647 Common Shares
Dec 09 2022	SELL Open market or private sale	$937,633 $7.03 p/Share	133,376 Reduced 13.05%	888,742 Common Shares
Dec 08 2022	SELL Open market or private sale	$82,103 $7.0 p/Share	11,729 Reduced 1.13%	1,022,118 Common Shares
Nov 20 2022	SELL Other acquisition or disposition	$80,015 $5.0 p/Share	16,003 Reduced 1.52%	1,033,847 Common Shares
Oct 25 2022	SELL Open market or private sale	$70,057 $4.4 p/Share	15,922 Reduced 1.49%	1,049,850 Common Shares
Sep 23 2022	SELL Open market or private sale	$53,393 $3.07 p/Share	17,392 Reduced 1.61%	1,065,772 Common Shares
Aug 24 2022	SELL Open market or private sale	$61,326 $3.71 p/Share	16,530 Reduced 1.5%	1,083,164 Common Shares
Jul 25 2022	SELL Open market or private sale	$73,160 $4.33 p/Share	16,896 Reduced 1.51%	1,099,694 Common Shares
Jun 23 2022	SELL Open market or private sale	$71,185 $4.34 p/Share	16,402 Reduced 1.45%	1,116,590 Common Shares
May 20 2022	SELL Open market or private sale	$504,758 $3.7 p/Share	136,421 Reduced 10.75%	1,132,992 Common Shares

Also insider at

IMVT

Immunovant, Inc. Healthcare

Chief Executive Officer

Eric Venker

President & Immunovant CEO

London, X0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ROIV shares.

Notify only if

Value

Insider Trading

Get notified when an Roivant Sciences Ltd. insider buys or sells ROIV shares.

Notify only if

Operation

Value

Type

News

Receive news related to Roivant Sciences Ltd.

Track Activities on ROIV

Account